Biotechnology and Medical Research

November 03, 2017

Companies covered: Illumina, Inc. (NASDAQ:ILMN), Pacific Biosciences of California, Inc. (NASDAQ:PACB), Quidel Corporation (NASDAQ:QDEL), Meridian Bioscience Inc. (NASDAQ:VIVO), Bio-Rad Laboratories, Inc. (NYSE:BIO), Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY), Danaher Corporation (NYSE:DHR), Thermo Fisher Scientific Inc (NYSE:TMO), Quest Diagnostics Incorporated (NYSE:DGX), Laboratory Corporation of America Holdings (NYSE:LH), IDEXX Laboratories, Inc. (NASDAQ:IDXX), Neogen Corporation (NASDAQ:NEOG), ABAXIS, Inc. (NASDAQ:ABAX), Heska Corporation (NASDAQ:HSKA), LHC Group (NASDAQ:LHCG), Amedisys Inc (NASDAQ:AMED), The Ensign Group, Inc. (NASDAQ:ENSG), HealthSouth Corporation (NYSE:HLS), CareTrust REIT, Inc. (NASDAQ:CTRE), Acadia Healthcare Company, Inc. (NASDAQ:ACHC), UnitedHealth Group Incorporated (NYSE:UNH), Sabra Healthcare REIT, Inc. (NASDAQ:SBRA), Abbott Laboratories (NYSE:ABT), GenMark Diagnostics, Inc. (NASDAQ:GNMK), Luminex Corporation (NASDAQ:LMNX), BioMerieux SA (EPA:BIM), Accelerate Diagnostics, Inc. (NASDAQ:AXDX), EXACT Sciences Corporation (NASDAQ:EXAS), Glaukos Corp (NYSE:GKOS), Cooper Companies, Inc. (The) (NYSE:COO), Teleflex Incorporated (NYSE:TFX), Becton, Dickinson and Company (NYSE:BDX), Alere Inc. (NYSE:ALR), C.R. Bard, Inc. (NYSE:BCR), Hologic, Inc. (NASDAQ:HOLX), Masimo Corporation (NASDAQ:MASI), General Electric Company (NYSE:GE), Siemens AG (OTCMKTS:SIEGY), Fujifilm Sonosite Inc (NASDAQ:SONO), Allergan, Inc. (NYSE:AGN), Align Technology, Inc. (NASDAQ:ALGN), Trupanion, Inc. (NYSE:TRUP), Patterson Companies, Inc. (NASDAQ:PDCO), Henry Schein, Inc. (NASDAQ:HSIC), DENTSPLY International Inc. (NASDAQ:XRAY), Sientra, Inc. (NASDAQ:SIEN), Omega Healthcare Investors, Inc. (NYSE:OHI), Genesis Healthcare, Inc. (NYSE:GEN), Healthcare Trust of America, Inc. (NYSE:HTA), Welltower Inc (NYSE:HCN), Ventas, Inc. (NYSE:VTR), Healthcare Realty Trust Incorporated (NYSE:HR), Physicians Realty Trust (NYSE:DOC), Care Capital Properties, Inc. (NYSE:CCP), HCP, Inc. (NYSE:HCP), Quality Care Properties (NYSE:QCP), InMed Pharmaceuticals, Inc. (OTCMKTS:IMLFF), Anavex Life Sciences Corp. (NASDAQ:AVXL), Oasmia Pharmaceutical AB (NASDAQ:OASM), Innovotech Inc. (CVE:IOT), NeuroVive Pharmaceutical AB (OTCMKTS:NEVPF), Nuevolution AB (NUE.ST)

Buy ($175)

Pin It on Pinterest

Share This